Quarterly report pursuant to Section 13 or 15(d)

4. Commitments and Contingencies (Details Narrative)

v3.20.2
4. Commitments and Contingencies (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Research and development expense $ 1,492,285 $ 42,730 $ 2,105,362 $ 91,037  
Technology Rights And Development Agreement [Member] | Houston Pharmaceuticals [Member]          
Contractual obligation 0 $ 45,833 0 45,833 $ 45,833
Royalty income     100,000 $ 0  
Patent and Technology License Agreement [Member] | UTMDACC [Member]          
Contractual obligation 30,000   30,000    
License fee     50,404    
Sponsored Research Agreement [Member] | UTMDACC [Member]          
Contractual obligation $ 734,000   734,000    
Research and development expense     $ 334,000